Cosmos Health Inc. (COSM)
| Market Cap | 12.15M |
| Revenue (ttm) | 53.55M |
| Net Income (ttm) | -21.33M |
| Shares Out | 28.66M |
| EPS (ttm) | -0.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 175,695 |
| Open | 0.4200 |
| Previous Close | 0.4164 |
| Day's Range | 0.4161 - 0.4372 |
| 52-Week Range | 0.2801 - 1.5800 |
| Beta | 4.14 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 18, 2025 |
About COSM
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United States, Croatia, Bulgaria, Ireland, the Cayman Islands, the UAE, the United Kingdom, and Cyprus. The company offers medicines, OTC medicines, nutraceutical products, vitamins, minerals, and dietary health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. It also provides ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltu... [Read more]
Financial Performance
In 2024, Cosmos Health's revenue was $54.43 million, an increase of 1.97% compared to the previous year's $53.38 million. Losses were -$22.38 million, -13.21% less than in 2023.
Financial StatementsNews
Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech
CHICAGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D...
RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
CHICAGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, ...
Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
CHICAGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, ...
Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D,...
Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D,...
Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000
CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&...
Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&...
Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L
CHICAGO, April 09, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&...
Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order
CHICAGO, April 08, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&...
Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates
CHICAGO, IL / ACCESS Newswire / February 26, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innov...
Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1
CHICAGO, IL / ACCESS Newswire / February 18, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innov...
Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market
Finalizing scale-up production phase Engaging with Contract Research Organizations to complete the technical dossier Clinical trials expected to complete in late 2025 or early 2026 Potential classific...
Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market
CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innov...
Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations
CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innov...
Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility
CHICAGO, IL / ACCESS Newswire / February 7, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innova...
Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar
CHICAGO, IL / ACCESS Newswire / February 6, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innova...
Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market
CHICAGO, IL / ACCESS Newswire / February 5, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovat...
Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow
CHICAGO, IL / ACCESS Newswire / January 28, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innova...
Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion
CHICAGO, IL / ACCESS Newswire / January 27, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innova...
Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait
CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovati...
Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million
Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and n...
Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days
Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and n...
Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries
CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&...
Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology
CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative...
Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000
CHICAGO, IL / ACCESSWIRE / December 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative...